Orally active 5-lipoxygenase (5-LOX) inhibitor that inhibits LTB4
values are 0.56, 2.3 and 2.6 μ
M in dog, rat and human blood respectively). Inhibits antigen-induced contraction of tracheal strips in vitro
= 6 μ
M) and exhibits antiasthmatic activity in vivo
. Also weakly inhibits CYP1A2 (Ki
= 66 - 98 μ
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase.
McMillan et al.
The 5-lipoxygenase inhibitory activity of zileuton in in vitro and in vivo models of antigen-induced airway anaphylaxis.
Malo et al.
Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor.
Lu et al.
Drug Metab.Dispos., 2003;31:1352
The citations listed below are publications that use Tocris products. Selected citations for Zileuton include:
Showing Results 1 - 4 of 4